Shots:

• The company reported the initial lab results of its COVISTIX COVID-19 virus rapid antigen detection test which showed its ability to detect Omicron variant along with the original SARS-CoV-2 virus and other VOCs
• In a laboratory setting, COVISTIX can detect the Omicron N protein at a lower level over other COVID-19 rapid antigen tests that were EUA approved and commercially available. Additionally, COVISTIX demonstrated ~20% higher sensitivity in a real-world clinical study including asymptomatic patients
• COVISTIX is currently approved in Mexico, Brazil and is CE marked in the EU. The company is currently building up its manufacturing capacity in the US

Ref: Globe Newswire | Image: Sorrento